netFormulary Dorset NHS
The Dorset Formulary has been developed in associations with
NHS Dorset Clinical Commissioning Group
Dorset County Hospital NHS Foundation Trust
Dorset Healthcare University NHS Foundation Trust
Poole Hospital NHS Foundation Trust
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
 
 Search
 Results

Looking for Aflibercept found 14 matches

Formulary BNF Category
  Aflibercept  (Eylea) Subfoveal choroidal neovascularisation - 11.08.02
 
Non Formulary BNF Category
  Cytotoxic Drug Aflibercept  (Zaltrap) Cytotoxic drugs - 08.01


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307) (08.01.05)
link in drug section Commissioning statement aflibercept for neovascular (wet) AMD (11.08.02)
link in drug section Commissioning statement aflibercept for visual impairment caused by macular oedema secondary to retinal vein occlusion (11.08.02)
link in drug section Commissioning statement for aflibercept in diabetic macular oedema (11.08.02)
link in drug section Commissioning Statement on the use of aflibercept for treating choroidal neovascularisation in accordance with NICE TA486 (11.08.02)
link in drug section NICE TA 307 - Aflibercept in combination with Irinotecan and Fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (11.08.02)
link in drug section NICE TA294: aflibercept solution for injection for treating wet age-related macular degeneration (11.08.02)
link in drug section NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (11.08.02)
link in drug section NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy  (08.01)
link in drug section NICE TA346 Aflibercept for treating diabetic macular oedema (11.08.02)
link in drug section NICE TA409 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (11.08.02)
link in drug section NICE TA486: Aflibercept for treating choroidal neovascularisation (11.08.02)


 

netFormulary